This article was downloaded by: [New York University] On: 03 June 2015, At: 11:03 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lncn20</u>

Synthesis of a Novel, Optically Active Uridine Analog Containing a 1,4-Dioxane Sugar Moiety. Synthesis of the Corresponding Dinucleotide

Qiang Yu^a & Per Carlsen^a

^a Department of Chemistry , Norwegian University of Science and Technology, NTNU , Trondheim, Norway Published online: 30 Mar 2009.

To cite this article: Qiang Yu & Per Carlsen (2009) Synthesis of a Novel, Optically Active Uridine Analog Containing a 1,4-Dioxane Sugar Moiety. Synthesis of the Corresponding Dinucleotide, Nucleosides, Nucleotides and Nucleic Acids, 28:3, 220-237, DOI: <u>10.1080/15257770902865407</u>

To link to this article: <u>http://dx.doi.org/10.1080/15257770902865407</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

Nucleosides, Nucleotides and Nucleic Acids, 28:220–237, 2009 Copyright © Taylor & Francis Group, LLC ISSN: 1525-7770 print / 1532-2335 online DOI: 10.1080/15257770902865407



SYNTHESIS OF A NOVEL, OPTICALLY ACTIVE URIDINE ANALOG CONTAINING A 1,4-DIOXANE SUGAR MOIETY. SYNTHESIS OF THE CORRESPONDING DINUCLEOTIDE

Qiang Yu and Per Carlsen

Department of Chemistry, Norwegian University of Science and Technology, NTNU, Trondheim, Norway

□ A new optically active uridine nucleoside analogue in which a substituted 1,4-dioxane ring functioned as the sugar analogue was prepared from L-tartaric acid. The nucleoside analogue was further converted into the corresponding protected dinucleotide.

Keywords Uridine analogs; 1,4-dioxane; nucleoside analogs; dinucleotide analogs; optically active; heterocycle

INTRODUCTION

Nucleosides analogs have been a subject of considerable interest due to their potential biologic activities. In the search for new antiviral and antitumor agents, a number of nucleoside analogs have in recent years been synthesized in with the sugar moiety was modified,^[1] and examples in which the sugar unit was replaced by a 1,4-dioxane group have been reported, in attempts to develop novel therapeutics.^[2] Some were reported to have interesting biological activities.^[2a,2b] Such an analogue may be more potent and/or selective, due to their conformational properties.^[2c] Most of the reported nucleoside analogs with 1,4-dioxane groups replacing the sugar in the natural nucleosides were substitutes so that formation of polynucleotides was not possible. Few of the products described in these publications were optically active.

We here report the synthesis a new optically active nucleoside analog that consist of a 1,4-dioxane ring, substituted with uracil and a 1,2-

Received 24 June 2008; accepted 4 March 2009.

The authors wish to thank the Norwegian Research Council (NFR) for generous financial support. Address correspondence to Per Carlsen, Department of Chemistry, Norwegian University of Science and Technology, NTNU, N-7491, Trondheim, Norway. E-mail: per.carlsen@chem.ntnu.no



1a:1a-anomer, *trans*-isomer **1b**:1a-anomer, *cis*-isomer



dihydroxyethyl substituent (Figure 1). With the dihydroxyethyl substituent is in the equatorial position, the uracil base is in either of the anomeric positions, thus the dihydroxyethyl substituent and the uracil ring are of either *trans*- or *cis*-configurations. This uridine analog was further elaborated into the corresponding dinucleotide using the standard phosphoraimidite procedure.^[3] An additional objective was to establish if nucleoside **1** was a suitable substrate for the preparation of new oligonucleotides.

RESULTS AND DISCUSSION

As the biologic activities of enantiomers are usually quite different, an important objective in the work was to develop a synthetic procedure that effortlessly produced either of the possible stereoisomers corresponding to structure 1, that is, either of the four possible isomers of each anomer. The chirality of the 1,4-dioxane system was introduced through the use of tartaric acid, in this work exclusively *L*-tartaric acid, 2, (*R*,*R*-tartaric acid). All the tartaric acid stereoisomers are inexpensive and readily available chiral pool materials.

Initially (2R,3R)-dimethyl tartrate was converted into the corresponding enantiomerically pure allyl ether 3 either by the reaction with allyl bromide in the presence of silver oxide^[4] or in a tin assisted reaction with dibutyltin oxide.^[5] Allylether **3** was next reduced to triol **4**, either using $\text{LiAlH}_4^{[\acute{6}]}$ in 26% isolated yield, or as a viable alternative by reduction with NaBH₄^[7] which gave 4 in 88% yield. The latter product contained minor borate impurities, but could be used in the subsequent steps without further purification. Ozonolysis of 4 gave the corresponding aldehyde 5, which however spontaneously converted into the corresponding hemiacetals 6 and 7 (Scheme 1). NMR and IR measurements indicated the presence of no free aldehyde. Hemiacetal 6 was formed from 5 through ring closure with the C-3 OH group (route a), while hemiacetals 7 were obtained through ring closure with the C-1 OH group (route b). As expected separation of products 6 and 7 by chromatography was not successful. Assuming the hemiacetals being in equilibrium, it was expected that upon subjecting the mixture to acid catalyzed acetal formation with 2,2-dimethoxypropane, the more stable



SCHEME 1 Synthesis of chiral 1,4-dioxane sugar analogs 8 from L-dimethyl tartrate.

5-membered acetal **8** would be formed as the exclusive product. Diol **6** may form a less favorable 7-membered acetal. As it turned out, the desired product **8** was formed in mixture with unreacted **6**. Product **8** was isolated by flash chromatography, but obtained in merely 21% yield. That not all the components in the equilibria shown in Scheme 1 were channeled into acetal **8**, may be ascribed to the kinetic stability of hemiacetal **6** under the reaction conditions.

In order to obtain compound 8 in a better yield, the reaction sequence was altered. Thus, triol 4 was reacted with 2,2-dimethoxypropane with p-TsOH-catalysis to give the five-membered acetal 9 as the exclusive product, without any signs of the alternative seven-membered acetal. Ozonolysis of 9 gave after flash chromatography the desired 1,4-dioxane derivative 8 as the only product, isolated in 43% over-all yield from 3 (Scheme 2), as an approximately 1:1 mixture of the anomers. The stereochemistry of all stereogenic carbons were retained in all of these transformations, except for the anomeric hemiacetal carbon generated in the reaction sequence.



SCHEME 2 Alternative synthesis of 1,4-dioxane sugar analog 8.



SCHEME 3 Synthesis of 1,4-dioxane uracil analogs 1a and 1b.

For the introduction of the nucleic base into the pseudo-sugar, compound **8** was next acetylated with acetic anhydride in pyridine to give the mixture of anomeric acetates, **10** (Figure 3), which was then reacted in a TMSOTf-catalyzed reaction with silylated uracil^[9] according to the Vorbrüggen's procedure.^[8] This afforded nucleoside **11** (Figure 4), for which the acetal deprotection was removed using catalytic amount of Amberlyst 15 in methanol. This gave the desired uridine analog anomers **1a** and **1b**, as an approximately 4:1 mixture as indicated by NMR (Scheme 3) and in 59% isolated yield from compound **8**. Anomer, **1a** (Figure 5), was isolated in 42% yield from the reaction mixture by recrystallization from acetonitrile. The anomers were also readily separated by flash chromatography.

The structures of nucleoside analog **1a** and **1b** are shown in Figure 2, and were elucidated by ¹H- and ¹³C-NMR, by DEPT and the various 2D-NMR



1a

1b

FIGURE 2 Structures of anomers 1a and 1b.

techniques, COSY, HSQC, HMBC, NOESY. In the ¹H NMR spectrum of **1a**, a relatively large J_{FE2} value (10 Hz) was observed, which indicated that H_F occupied the axial position, uracil thus occupying the equatorial position. The coupling constants J_{CD1} (11.2 Hz) and J_{CD2} (2.8 Hz) provided evidence that H_{D1} was in the axial position and H_{D2} was equatorial, and H_C was in an axial position. The 2D-NOESY experiment of **1a** showed a clear NOE effect between H_F and H_{D1} . These data were in agreement with **1a** being the *trans*compound. For diastereomer **1b**, in the ¹H-NMR the coupling constants $J_{F'E1'}$ and $J_{F'E2'}$ were measured to 1.2 Hz and 3.7 Hz, respectively, indicating $H_{F'}$ to be in the equatorial position, hence the uracil group in the axial position. 2D-NOESY experiment with **1b** showed a clear NOE effect between $H_{G'}$ and $H_{E1'}$.

In modern polynucleotide chemistry, building oligonucleotides is usually done using solid support methods and automated synthesis machines. It was not planned here to prepare larger oligomers, but rather to elucidate if the dioxane nucleoside analogs were capable of undergoing the necessary transformations for such automated procedures. For this reason a batch procedure including the preparation of key intermediates and transformations were studied. To prepare the uridine dinucleotide analog, the phosphoramidite procedure^[3] was adopted because this is extensively used in the solid phase synthesis of oligonucleotides. Uridine analog **1a** was thus reacted with 4, 4'-dimethoxyltrityl chloride in pyridine to afford primary hydroxyl group protected compound **12** (Figure 6).^[10] Compound **12** was next treated with 2-cyanoethyl *N*,*N*-diisopropylphosphoramido chloride in the presence of *N*,*N*-diisopropylethylamine in anhydrous dichloromethane^[11] at room temperature affording the desired intermediate **13** (Scheme 4



 $\frac{\mathsf{NC}(\mathsf{CH}_2)_2\mathsf{OP}(\mathsf{CI})\mathsf{N}(iso-\mathsf{Pr})_2}{\mathsf{CH}_2\mathsf{CI}_2} \xrightarrow{\mathsf{DMTrO}} \overset{\mathsf{PO}}{\underset{\mathsf{H}}{\mathsf{O}}} \overset{\mathsf{O}}{\underset{\mathsf{H}}{\mathsf{O}}} \overset{\mathsf{O}}{\underset{\mathsf{O}}{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{\underset{\mathsf{O}}{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{\mathsf{O}}}} \overset{\mathsf{O}}{{\mathsf{O}}} \overset{\mathsf{O}}{{$

SCHEME 4 Synthesis of nucleoside phosphite analog 13.



SCHEME 5 Synthesis of uracil acetate analog 14.

and Figure 7). Interestingly, the two diastereomers generated due to the presence of the phosphite stereogenic center, were separated by chromatog-raphy on a silica gel column.

To obtain the other component required for the coupling scheme towards the protected dinucleotide **16**, intermediated **12** was first acylated with acetic anhydride in pyridine to afford compound **15** (Figure 8) and the trityl group was subsequently removed using dichloroacetic acid providing the desired primary alcohol **14** (Scheme 5 and Figure 9).

The uracil dinucleotide **16** was then prepared by coupling **13** with **14** in the presence of tetrazole in dry acetonitrile,^[12] followed by iodine oxidation of the phosphite moiety to the desired protected phosphate group. The product was purification by flash chromatography on silica gel (Scheme 6). Dinucleotide **16** was formed as a diastereomeric mixture due to the phosphate stereogenic center. This resulted in rather complex ¹H-NMR spectrum. The ³¹P NMR spectrum shows two strong signals at -1.83 and -1.90 ppm together with two very small signals at 9.0 ppm and 8.3 ppm, indicating the crude product to be of reasonable good purity. Compound **16** was further purified by column chromatography.

The synthesis was not extended beyond this point, as product **16** may now function as substrate for further oligomerization reactions, or be deprotected to give the parent uridine dinucleotide analog.

CONCLUSIONS

In conclusion, the uridine 1,4-dioxane nucleoside analog 1 was readily prepared from tartaric acid. This compound was further converted into the corresponding partially protected dinucleotide, hence demonstrating that



SCHEME 6 Synthesis of the protected uracil dinucleotide analog 16.

the uridine nucleoside analog may be elaborated into larger oligomers using established standard procedure.^[13]

EXPERIMENTAL

NMR spectra were recorded on Bruker Avance DPX 300 or DPX 400 instruments (Bruker, Germany). Chemical shifts are reported in ppm using TMS (0.0) as the internal standard in CDCl₃ or relative to 2.50 ppm for ¹H and 39.99 ppm for ¹³C in [D₆-DMSO] or 3.31 ppm for ¹H and 49.15 ppm for ¹³C in CD₃OD. Structural assignments were based on ¹H, ¹³C, DEPT135 and 2D spetra, COSY, HSQC, HMBC, NOESY. EI-Mass, and ESI spectra were recorded on a Finnigan MAT 95XL spectrometer (Finnegan MAT AB, Sweden). IR spectra were obtained on a FT-IR Nexus spectrometer (Thermo-Nicolet, USA) using a Smart Endurance reflection cell. For ozonolysis was used an OZ-500 Ozone Generator produced by Fischer Technology (Germany). Silica gel Kieselgel 60G (Merck) was used for Flash Chromatography. The solvents were purified by standard methods.

(2R,3R)-Dimethyl 2-(allyloxy)-3-hydroxysuccinate, 3

This compound was prepared from dimethyl *l*-tartrate, **2**, as described earlier^[14] either by reaction with allyl bromide and silver oxide,⁴ resulting

in variable yields between 20 and 84% or by a reaction involving dibutyltin oxide⁵ resulting in a 70% overall yield. B.p. 90°C at 10^{-3} torr. The spectroscopic properties were in agreement with those reported previously.^[5]

(2S,3S)-3-(Allyloxy)butane-1,2,4-triol, 4

This product was obtained by reduction of $\mathbf{3}$ with either LiAlH₄ or NaBH₄.

LiAlH₄ reduction: To a suspension of LiAlH₄ (3.72 g, 95%, 93 mmol) in dry diethyl ether (50 mL) was drop wise added a solution of **3** (4.36 g, 20 mmol) in 4 mL of diethyl ether at 0–5°C. The reaction mixture was refluxed for 18 hours and then cooled in an ice bath. Then 5 mL of water was added and the mixture stirred for 20 minutes, followed by addition of a 15% NaOH solution (12 mL) and then 10 mL of water. The resulting mixture was stirred and the granular salt formed, was separated by filtration, washed with hot THF (200 mL), and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (CHCl₃/CH₃OH, 9:1 mixture) to give 0.83 g, 26% of the pure product **4**.

NaBH₄ reduction. Sodium borohydride (3.45 g, 93 mmol) in ethanol (50mL) was stirred for half an hour and then dropwise added a solution of **3** (4.35 g, 20 mmol) in ethanol (15 mL). The resulting solution was refluxed gently for 5 hours. The solution was cooled in an ice bath and added 10 mL of acetic acid. The mixture was stirred for 20 minutes and filtered. The solid was washed with 2×50 ml ethanol. The combined organic phase was concentrated under reduced pressure. The crude product was purified by flash chromatography using a 19:1 mixture of CH₂Cl_{2/}MeOH as the eluent yielding 2.88 g, 88% of the pure product, which exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400 MHz): $\delta = 3.45$ (q, 1H, CH-OAllyl), 3.66–3.74 (m, 3H, 1H from CH₂-CHOH, 2H from CH₂-CH-OAll), 3.80 (dd, 1H from CH₂-CHOH), 3.86 (q, 1H, CHOH), 4.03-4.20 (m, 2H, OCH₂-CH=CH2), 4.32 (s, broad, 3H, OH), 5.18-5.38 $(m, 2H, CH_2 = CH), 5.86-5.96 (m, 1H, CH=CH2) ppm.^{13}C-NMR (CDCl3, CDCl3)$ 100MHz): $\delta = 60.6, 63.3, 71.6, 71.8, 79.1, 117.8, 134.5$ ppm. MS (EI) m/z: 145 (M⁺-OH), 131 (M⁺-CH2OH), 101 (OH-CH₂ = O⁺CH₂-CH=CH₂), 61 (HOCH₂CH=O+H). IR (neat): 3365, 2881, 1736, 1448 cm⁻¹

(S)-2-(Allyloxy)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol, 9

A solution of 4 (6.20 g, 38 mmol), 2,2-dimethoxylpropane (4.00 g, 38.5 mmol) and pTsOH (223 mg, 1.2 mmol) in 100 mL acetone was stirred overnight at room temperature. The solvent was then removed and the residue was purified by flash chromatography using a 3:2 mixture of Et_2O/n -hexane as the eluent to provide product 9 as colorless oil (5.11 g, 85%). Unreacted starting material 4 (1.05 g crude product) was recovered by

continued elusion with a 19:1 mixture of $CH_2Cl_2/MeOH$. Product **9** exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 1.37$ (s, 3H, CH₃), 1.44 (s, 1H, CH₃), 2.48 (s, broad, 1H, OH), 3.49–3.53 (m, 1H, CH-OAll), 3.59 (dd, J = 10.8Hz, 12Hz, 1H, HOCH₂-CHOAll), 3.73 (dd, J = 4.2Hz, 12Hz, 1H, HOCH₂-CHOAll), 3.81 (dd, J = 7.2Hz, 8.4Hz, 1H, COCH₂CHO-C), 4.03 (dd, J = 6.4Hz, 8.4Hz, 1H, C-OCH₂CHO-C), 4.18–4.22 (m, 2H, OCH₂-CH=CH₂), 4.26–4.31 (m, 1H, C-OCH₂CHO-C), 5.24–5.33 (m, 2H, CH₂ = CH), 5.88–5.95 (m, 1H, CH=CH₂) ppm.¹³C-NMR (CDCl3, 100MHz): δ 25.3, 26.4, 61.6, 65.4, 71.8, 76.4, 79.1, 109.4, 117.4, 134.7 ppm. MS: (EI) *m/z*: 202(M⁺), 187 (M⁺-CH₃), 171(M⁺-CH₂OH), 101(C₅H₉O₂⁺).

(2*R*,5*S*)-5-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyl-1,4 -dioxane, 8a, and (2*S*,5*S*)-5-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyl-1,4-dioxane, 8b

A solution of 9 (5.9 g, 29.2 mmol) in a mixed of methanol and dichloromethane (1:4) (200 mL) was ozonized at -78° C until a persistent blue color, 1 hour 45 minutes. The ozonolysis mixture was then purged until most of the blue color had disappeared and then added dimethyl sulfide (2.2 g, 35.5 mmol) and stirred overnight. The resulting mixture was concentrated under reduced pressure and the crude product purified by flash chromatography using a 7:3 mixture of Et_2O/n -hexane as the eluent, yielding the product as a colorless oil (4.62 g, 78%). The anomeric ration was approximately 1:1 as determined by NMR, however, the isomers were not separated. The product exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400 MHz): $\delta = 1.36$ (s, 3H, CH₃), 1.37(s, 3H, CH₃), 1.43 (s, 3H, CH₃), 1.44 (s, 3H, CH₃), 3.30 (dd, 8.4Hz, 11.2Hz, 1H, OCH₂CHOH-), 3.45 (dd, 11.6Hz, 2.8Hz, 1H, CHCH₂CHOH-), 4.84 (d, 8.4Hz, 1H, anomeric proton), 4.98 (d, 3.6Hz, 1H, anomeric proton), (3.55–3.66, m, 3H; 3.69–3.76, m, 1H; 3.78–3.84, m, 5H; 3.93–4.02, m, 3H; 4.05–4.16, m, 2H; the other protons). ¹³C-NMR (CDCl₃, 100MHz): δ 25.2, 26.22, 26.25, 59.3, 65.0, 65.1, 65.7, 69.2, 70.0, 74.29, 74.6, 74.9, 75.5, 88.7, 91.8, 109.8 ppm.

(2*S*,5*S*)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-acetyloxy-1,4 -dioxane, 10a, and (2*R*,5*S*)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-acetyloxy-1,4-dioxane, 10b

To a solution of **9** (1.0 g, 4.9 mmol) in 15mL of dry pyridine was added acetic anhydride (0.62 g, 6 mmol) at $0-5^{\circ}$ C and the reaction mixture was stirred for 6 hours. The solution was concentrated under reduced in vacuo overnight, yielding the crude product in 87% yield as a sticky oily material, which was used in the subsequent reaction step without further purification.



FIGURE 3 Structure 10a.

The anomeric ration **10a:10b** (*trans- cis-* ratio) was determined to 4:1 by NMR.

The product exhibited the following spectroscopic properties: NMR spectrum of *trans*- compound **10a** (Figure 3) was assigned the following signals: ¹H-NMR (CDCl₃, 400MHz): $\delta = 1.36$, 1.43 (s, 2×3H, (CH₃)₂C), 2.11 (s, 3H, CH₃COO), 3.48 (dd, J = 8.0Hz, 11.4Hz, 1H, H_{B1}), 3.63 (m, 1H, H_C), 3.69 (dd, J = 9.4Hz, 11.4Hz, 1H, H_{D1}), 3.81 (dd, J = 6.8Hz, 8.0Hz, 1H, (CH₃)₂C-O-CH₂), 3.89 (dd, J = 2.6Hz, 11.4Hz, 1H, H_{D2}), 3.93 (dd, 2.8Hz, 11.4Hz, 1H, H_{B2}), 4.00 (dd, 6.8Hz, 8.4Hz, 1H, (CH₃)₂C-O-CH₂), 4.15 (m, 1H, (CH₃)₂C-O-CH-), 5.74 (dd, 2.8Hz, 8.4Hz, 1H, H_A) ppm. ¹³C-NMR (CDCl₃, 100MHz): $\delta = 20.9$, 25.2, 26.3, 65.2, 65.6, 66.9, 74.2, 74.2, 89.4, 109.7, 169.0 ppm.

The protons NMR spectrum of the corresponding *cis*- compound, **10b**, could not be fully assigned due to the peaks overlap with **10a**. The carbons NMR spectrum of the *cis*- compound was assigned the following signals: ¹³C-NMR (CDCl₃, 100MHz): $\delta = 21.1$, 25.2, 26.2, 61.0, 64.9, 67.6, 74.9, 75.1, 88.4, 109.7, 169.8 ppm.

The mixture exhibited the following mass spectrum: MS (EI) m/z: 247 (M⁺+1), 231(M⁺-CH₃), 187(M⁺-OAc), 145 (C₆H₉O₄). Elem. Anal. calcd. for C₁₃H₁₈N₂O₆: C 53.65, H 7.37; found C, 53.84, H 7.45.

1-[(2*R*,5*S*)-5-[(4*S*)-(2,2-dimethyl-1,3-dioxolan-4-yl)]-1,4-dioxan -2-yl]uracil, 11a, and 1-[(2*S*,5*S*)-5-[(4*S*)-(2,2-dimethyl-1,3-dioxolan-4-yl)]-1,4-dioxan-2-yl]uracil, 11b

A mixture of uracil (0.92 g, 8.2 mmol) in 40 mL of hexamethyldisilazane (HMDS) was refluxed overnight. The resulting solution was concentrated and the residue was dissolved in 15 mL of dichloroethane. The solution was added **10** (0.48 g, 2 mmol) and the mixture was cooled to $0-5^{\circ}$ C and added TMSOTf (0.37 mL, 2mmol). After 5 hours of stirring the mixture was added 60 mL dichloromethane, which was washed twice with 15 mL of



11a

FIGURE 4 Structure 11a.

a saturated aqueous sodium bicarbonate solution. The aqueous phase was extracted once with 50 mL chloroform, and the combined organic phase was washed with 20 mL saturated solution of NaCl, dried over anhydrous MgSO₄ and filtered. The filtrate was concentrated under reduced pressure to give product **11** as a light yellow solid (0.37 g, 63.7%).

The *trans-cis*-ratio of the diastereomers was determined to 4:1 (NMR). The *trans*-compound **11a** (Figure 4) was assigned the following NMR signals: ¹H-NMR (CDCl₃, 400MHz): $\delta = 1.35$, 1.43 (s, 2×3H, H_A and H_B), 3.40 (dd, 10Hz, 11.2Hz, 1H, H_{G1}), 3.78–3.89 (m, 2H, H_{C1}+H_{F1}), 3.94–4.06 (m, 3H, H_{C2}+ H_{G2}+H_{F2}), 4.10–4.17 (m, 2H, H_D+ H_E), 5.74–5.77 (m, 1H, H_H), 5.76 (d, J = 8.4Hz, 1H, H_J), 7.41 (d, J = 8.4Hz, 1H, H_I), 9.70 (s, 1H, H_K) ppm. ¹³C-NMR (CDCl₃, 100MHz): $\delta = 25.10$, 26.2, 64.9, 68.1, 68.3, 74.3, 74.5, 78.5, 102.9, 109.9, 139.4, 150.0, 163.2 ppm. It was not possible to fully assign the protons NMR spectrum of the *cis*-compound due to the overlap of the peaks with those of **11a**. The carbons NMR signals of the *cis*-compound were assigned as follow: ¹³C-NMR (CDCl₃, 100MHz): $\delta = 25.1$, 26.1, 61.8, 64.9, 66.2, 74.37, 74.41, 75.4, 101.8, 110.0, 142.3, 151.1, 163.3 ppm. MS (EI) *m/z*: 298(M⁺), 283 (M⁺-CH₃), 187 (M⁺-uracil). IR (neat): 3197, 3098, 3065, 2986, 2937, 1688, 1452 cm⁻¹. Elem. anal.: Calcd. for C₁₃H₁₈N₂O₆: C 52.34, H 6.08, N 9.39; Found C, 52.43, H 6.41, N 9.23.

1-[(2*R*,5*S*)-5-[(1*S*)-1,2-dihydroxyethyl]-1,4-dioxan-2-yl]uracil, 1a, and 1-[(2*S*,5*S*)-5-[(1*S*)-1,2-dihydroxyethyl]-1,4-dioxan-2-yl] uracil, 1b

Compound 11 (0.35 g, 1.2 mmol) in 20 mL of methanol was refluxed for 2.5 hours in the presence of 50 mg of Amberlyst-15. The hot solution was filtered and the filtrate was cooled to room temperature. A white solid precipitated and was isolated by filtration. The product was dried *in vacuo* to give a pure *trans*-product 1a (101 mg, 42%). NMR analysis of the concentrated crude product showed a 4:1 *trans-cis*-ratio (1a:1b = 4:1).



FIGURE 5 Structure 1a.

Product **1a** (Figure 5) exhibited the following spectroscopic properties: ¹H-NMR ([D₆]DMSO, 400MHz): δ = 3.33 (dd, 12.8Hz, 16Hz, 1H, H_{A1}), 3.39–3.45 (m, 2H, H_{A2} + H_B), 3.58 (dd, 10Hz, 11.2Hz, 1H, H_{E2}), 3.62 (dt, 2.8Hz, 2.8Hz, 11.2Hz, 1H, H_C), 3.78 (dd, 11.2Hz, 11.6Hz, 1H, H_{D1}), 3.83 (dd, 2.8Hz, 11.2Hz, 1H, H_{E1}), 3.96 (dd, 2.8Hz, 11.6Hz, 1H, H_{D2}), 4.61 (s, br. 2H, -OH), 5.53 (dd, 2.8Hz, 10Hz, 1H, H_F), 5.62 (dd, 2.4Hz, 8.0Hz, 1H, H_H), 7.69 (d, 8.0Hz, 1H, H_G), 11.41 (d, 2.4Hz, 1H, NH) ppm.¹³C-NMR ([D₆]DMSO, 100MHz) δ 61.9, 67.0, 68.3, 70.4, 74.6, 77.9, 101.9, 140.9, 150.1, 162.9 ppm. IR (neat): 3478.9, 3430.3, 3032.2, 1704.1, 1674 cm⁻¹. MS (EI) *m/z*: 258(M⁺), 197(M⁺-(OHCHCH₂OH)), 147(M⁺-uracil). HRMS (ESI) *m/z*: for C₁₀H₁₄N₂O₆ [M+Na]⁺ calcd, 281.0750; found 281.0746. Elem. anal.: Calcd, for C₁₀H₁₄N₂O₆: C 46.51, H 5.46, N 10.85; Found C 46.33, H 5.32, N 10.80. [α] ²⁵_D +41.5 (c = 0.248, DMSO).

1-[(2*R*,5*S*)-5-[(1*S*)-hydroxy-2-(4,4'-dimethoxytrityl)-ethyl-1-yl]-1,4dioxan-2-yl]uracil, 12

Compound **1a** (286 mg, 1.11 mmol) in dry pyridine (18 mL) was added 4, 4-dimethoxytrityl chloride (0.41g, 1.15mmol) at room temperature under nitrogen. The reaction mixture was stirred for 3 hours and the solution then concentrated to half volume and then added 50 mL of ethyl acetate. The resulting solution was washed with 3×10 mL of saturated NaHCO₃ solution. The aqueous phase was extracted with 50 mL ethyl acetate. The combined organic phase was dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using ethyl acetate as the eluent to afford product **12** as a white solid (0.58 g, 93%).

The product **12** (Figure 6) exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 2.50$ (d, 5.6Hz, 1H, OH), 3.17 (dd, 10Hz, 5.4Hz, 1H, H_{A1}), 3.27 (dd, 10Hz, 5.6Hz, 1H, H_{A2}), 3.37 (dd, 10.2Hz, 11.2Hz, 1H, H_{E2}), 3.62–3.67 (m, 1H, H_B), 3.71–3.75 (m, 1H, H_C), 3.79 (s, 2×3H, OCH₃), 3.78–3.84 (m, 1H, H_{D1}), 3.94 (dd, 2.0Hz, 11.6Hz, 1H, H_{D2}),



FIGURE 6 Structure 12.

4.02 (dd, 2.8Hz, 11.2Hz, 1H, H_{E1}), 5.69 (dd, 2.8Hz, 9.6Hz, 1H, H_F), 5.74 (d, 8.4Hz, 1H, H_H), 6.82–6.85, 7.16–7.33 (m, aromatic hydrogen), 7.41–7.43 (m, H_G and aromatic hydrogen), 9.08 (s, 1H, NH) ppm. ¹³C-NMR (CDCl₃, 100MHz): δ = 55.4, 60.6, 63.8, 68.4, 68.9, 70.1, 75.1, 78.7, 86.6, 102.9, 113.36, 113.41, 127.1, 128.1, 128.24, 129.3, 130.2, 135.9, 136.0, 139.6, 144.8, 150.0, 158.8, 163.0 ppm. IR (neat): 3427, 3201, 3061, 2999, 2836, 1687, 1508, 1247, 1031, 827, 756, 727, 702 cm⁻¹. MS (EI) *m/z*: 560.2(M⁺), 304.1(trityl), 273.1, 227.1, 197(M⁺-(OHCHCH₂OH)-trityl group). HRMS (ESI) *m/z*: for C₃₁H₃₂N₂O₈ [M+Na]⁺ calcd, 583,2057; found 583.2050. Elem. anal.: calcd. for C₃₁H₃₂N₂O₈: C 66.42, H 5.75, N 5.00; found C 66.42, H 5.94, N 4.50.

1-[(2*R*,5*S*)-5-[(1S)-O-[2-cyanoethoxy(diisopropylamino) phosphino]-2-O-(4,4'-dimethoxy-trityl)-ethyl-1-yl]-1,4-dioxan-2yl]uracil, 13

Compound 12 (275 mg, 0.49 mmol) in 10 mL of dry dichloromethane was added *N*,*N*-diisopropylethylamine (0.18 mL, 1.0 mmol) under nitrogen. To this solution was added 2-cyanoethyl *N*,*N*-diisopropylphosphoramido chloride (0.2 mL, 0.90 mmol). The reaction mixture was stirred for four hours. The solution was then added 20 mL of dichloromethane and washed with 2 × 5ml of a saturated NaHCO₃ solution and then with 10 mL of brine. The organic phase was dried over anhydrous Na₂SO₄, filtered and the solvent evaporated. The residue was purified by flash chromatography using a 9:1 mixture of ethyl ether and *n*-hexane as the eluent to afford three fractions of 13a (70 mg, 17.7%) and 13b (110 mg, 27.8%) and a mixture (60 mg, 15.2%) of 13a and 13b. Compounds 13a and 13b were the diastereomers due to the stereogenic centre of phosphorus.

Compound **13a** (Figure 7) exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 1.19$ (d, 4Hz, 2×3H, H_J), 1.21 (d, 4Hz, 2×3H, H_I), 2.42 (t, 6.6Hz, 2H, H_L), 3.09 (dd, 9.6Hz, 4.8Hz, H_A), 3.34



FIGURE 7 Structure 13.

 $(dd, 11.2Hz, 10Hz, H_{E2}), 3.41 (dd, 9.6Hz, 5.2Hz, H_A), 3.59-3.67 (m, 1H, 1H, 11.2Hz), 10Hz, 10Hz,$ H_{I}), 3.66–3.73 (m, 2H, H_{K}), 3.72–3.79 (m, 1H, H_{D}), 3.79 (s, 3H, OCH₃), 3.80 (s, 3H, OCH₃), 3.81–3.86 (m, H_C), 3.93–4.01 (m, 3H, H_B, H_D and H_{E1}), 5.65 (dd, 9.6Hz, 2.8Hz, 1H, H_F), 5.74 (d, 8Hz, 1H, H_H), 6.80–6.86 (m, 4H, Aromatic H), 7.42-7.46 (m, Aromatic H), 7.20-7.25 (Aromatic H and H_G), 8.85 (broad s 1H, H_L) ppm. ¹³C-NMR (CDCl₃, 100MHz): δ = 19.7, 19.8, 24.10, 24.16, 24.18, 24.22, 42.8, 42.9, 54.8, 57.7, 57.8, 62.1, 67.9, 68.1, 72.5, 74.7, 78.1, 85.9, 102.2, 112.2, 117.1, 126.4, 127.4, 127.7, 129.6, 135.3, 135.5, 139.1, 144.3, 149.2, 158.1, 162.2, 174.5 ppm. ³¹P (85% H₃PO₄): 151.7 ppm. Product **11b** exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 1.10$ (d, 6.8Hz, 2×3H, H_I), 1.17 (d, 6.8Hz, 2×3H, H_I), 2.64 (dt, 6.4Hz, 0.4Hz, 2H, H_L), 3.15 (dd, 9.5Hz, 5.8Hz, H_A), 3.28 (dd, 9.5Hz, 5.6Hz, H_A), 3.40 (dd, 9.6Hz, 11.2Hz, H_E), 3.52-3.62 (m, 1H, H_I), 3.72-3.78 (m, 2H, H_K), 3.79 (s, 2×3 H, OCH₃), 3.82-3.89 (m, 1H, H_D), 3.90–3.95 (m, 1H, H_B), 3.95 (dd, 11.2, 3.2Hz, H_{E1}), 4.00–4.07 (m, 2H, H_D and H_C), 5.66 (dd, 9.6Hz, 2.8Hz, 1H, H_F), 5.73 (d, 8.2Hz, 1H, H_H), 6.80–6.85 (m, 4H, Aromatic H), 7.18–7.12 (m, 1H, Aromatic H) 7.25-7.30 (m, 2H, Aromatic H), 7.31-7.36 (m, 4H, Aromatic H), 7.43-7.46 (m, 2H, Aromatic H), 7.48 (d, 8.2Hz, 1H, H_G), 8.71 (broad s, 1H, N-H) ppm. ¹³C-NMR (CDCl₃, 100MHz): $\delta = 20.67, 20.74, 24.72, 24.80, 24.88,$ 24.94, 55.4, 58.1, 58.3, 62.7, 62.8, 68.6, 68.9, 72.6, 72.8, 75.28, 75.3, 78.7, 86.5, 102.8, 113.3, 127.0, 128.0, 128.3, 130.2, 130.3, 136.1, 136.2, 140.0, 145.0, 150.0, 158.7, 162.9 ppm. ³¹P (85% H₃PO₄): 151.3 ppm. IR (neat): 3204, 3064, 2965, 2931, 2874, 1693, 1508, 1248, 1177, 1029, 757, 726, 702



cm⁻¹. HRMS (ESI) m/z: Calcd. for C₄₀H₄₉N₄O₉P [M+H]⁺ 783.3135; found 783.3127. Elem. Anal.: Calcd. for C₄₀H₄₉N₄O₉P: C 63.15, H 6.49, N 7.36, P 4.07; found C, 63.03, H 6.52, N 7.25, P 3.96.

1-[(2R,5S)-5-[(1S)-acetyloxy-2-(4,4'-dimethoxytrityl)-ethyl-1-yl]-1,4-dioxan-2-yl]uracil, 15

Compound 12 (940 mg, 1.7 mmol) in 10 mL of dry pyridine was added acetic anhydride (360 ml, 3.4 mmol) at $0-5^{\circ}$ C under an atmosphere of nitrogen. The mixture was stirred overnight. The mixture was the concentrated under reduced pressure and the residue was purified by flash chromatography using a 9:1 mixture of ethyl acetate and n-hexane as the eluent to afford product 15 (988 mg, 98%).

The product **15** (Figure 8) exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 2.15$ (s, 3H, CH₃), 3.15 (dd, 10Hz, 5.2Hz, 1H, H_A), 3.32 (dd, 10Hz, 5.6Hz, 1H), 3.34 (dd, 11.6Hz, 10Hz, 1H, H_{E2}), 3.61–3.78 (m, 1H, H_D), 3.79 (s, 2×3H, OCH₃), 3.89–3.95 (m, 2H, H_C and H_D), 3.97 (dd, 11.4Hz, 3Hz, 1H, H_{E1}), 5.07 (dd, 9.6Hz, 5.2Hz, 1H, H_B), 5.69 (dd, 10Hz, 2.8Hz, 1H, H_F), 5.75 (d, 8Hz, 1H, H_H), 6.81–6.85 (m, 4H, aromatic H), 7.20–7.22 (m, 1H, aromatic H), 7.27–7.32 (m, 6H, aromatic H), 7.40–7.44 (m, 3H, aromatic H and H_G), 9.42 (broad s, 1H, N-H) ppm. ¹³C-NMR (CDCl₃, 100MHz) $\delta = 21.0$, 55.2, 61.4, 68.3, 70.9, 73.4, 78.4, 86.3, 102.8, 113.2, 126.9, 127.91, 127.98, 129.9, 130.0, 135.5, 135.6, 139.4, 144.5, 149.5, 149.8, 158.6, 163.0, 170.3 ppm. IR (neat): 3188, 3060, 2934, 2837, 1692, 1508, 1244, 1030, 827, 757, 727, 703 cm⁻¹. HRMS (ESI) m/z: Calcd. for C₃₃H₃₄N₂O₉ [M+Na]⁺ 625.2162, Found 625.2152. Elem. Anal.: Calcd. for C₃₃H₃₄N₂O₉: C 65.77, H 5.69, N 4.65; found C 65.35, H 5.76, N 4.73.



FIGURE 9 Structure 14.

1-[(2*R*,5*S*)-5-[(1*S*)-acetyloxy-2-hydroxylethyl-1-yl]-1,4-dioxan-2-yl]uracil, 14

Compound 15 (849 mg, 1.4 mmol) in 25 mL of dry dichloromethane was added 40 mL solution of dichloroacetic acid (2%, v/v) in dichloromethane. The mixture was stirred for half an hour and quenched with 25 mL of a saturated aqueous NaHCO₃ solution. The separated aqueous phase was extracted with 3×40 mL dichloromethane. The combined organic phase was dried over anhydrous Na₂SO₄, and the solution the filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography, elution first with ethyl acetate then with methanol, to afford product 14 as a white solid (234 mg, 55%).

The product **14** (Figure 9) exhibited the following spectroscopic properties: ¹H-NMR (CD₃OD, 400MHz): $\delta = 2.07$ (s, 3H, CH₃), 3.58 (dd, 11.4Hz, 9.8Hz, 1H, H_{E2}), 3.70–3.74 (m, 1H, H_B), 3.77–3.82 (m, 1H, H_C), 3.92–3.98 (m, 2H, H_E and H_{D1}), 4.06 (dd, 11.6, 2.8Hz, 1H, H_{D2}), 4.13 (dd, 11.2, 6.4Hz, 1H, H_A), 4.16 (dd, 11.2Hz, 5.4Hz, 1H, H_A), 5.69 (dd, 10Hz, 2.8Hz, 1H, H_F), 5.70 (d, 8Hz, 1H, H_H), 7.71 (d, 8Hz, 1H, H_G) ppm. ¹³C-NMR (CD₃OD, 100MHz): $\delta = 20.9$, 66.4, 69.2, 69.4, 69.8, 76.0, 80.0, 103.1, 142.3, 151.9, 166.0, 172.8 ppm. IR (neat): 3477, 3190, 3110, 3074, 2996, 2879, 1697, 1268, 1105 cm⁻¹. MS (EI): 230.3, 197(M⁺-(CH₃COCHCH₂OH)), 189(M⁺-uracil). HRMS (ESI): Calcd. for C₁₂H₁₆N₂O₇ [M+Na]⁺ 323.0856, Found 323.0862. Elem. Anal.: Calcd. for C₁₂H₁₆N₂O₇: C 48.00, H, 5.37, N, 9.33; found C, 47.51, H, 5.46, N, 9.85.

Dinucleotide Analog 16

Compound 14 (8 mg, 0.027 mmol) and compound 13 (30 mg, 0.039 mmol) with a magnetic stirring bar were dried in high vacuo over night. The mixture was then added 6 mL of dry acetonitrile and 0.3 mL of 1-H tetrazole (0.45 M in acetonitrile). The resulting solution was stirred for 15 hours and then added a solution of iodine (1M in a mixture of THF, 2,6-lutidine and

H₂O (2:2:1) until a persistent orange color. The solution was quenched with a saturated sodium thiosulfate solution, and then added 4 mL of a saturated NaHCO₃ solution and the phases separated. The aqueous phase was extracted with dichloromethane 4×8 mL. The combined organic phase was dried over anhydrous Na₂SO₄, filtered and then concentrated under reduced pressure. The crude product was purified by flash chromatography using gradient elution of the mixture of dichloromethane and methanol (25:1, 15:1). The product, 16, was obtained as a white product, 16 mg, 62% yield. The product exhibited the following spectroscopic properties: ¹H-NMR (CDCl₃, 400MHz): $\delta = 2.09$, 2.11 (s, CH₃COO), 2.50–2.67 (m, CH₂CN), 2.71–2.75 (m, CH₂CN), 3.14–3.25, 3.38–3.52, 4.04–4.10 (m, CH₂-CH-Uracil), 3.79, 3.80 (s, OCH₃), 4.17–4.23 (m, OCH₂CH₂CN), 5.61–5.78 (m, CH=CH-CO in uracil and anomeric H), 6.81–6.86 (m, aromatic protons), 7.22-7.32 (aromatic protons and CH = CH-CO in uracil), 7.38-7.44(aromatic protons and CH = CH-CO in uracil), 3.64-3.69, 3.72-3.81, 3.84-3.98, 4.21-4.33, 4.37-4.44, 4.52-4.67 (m, the other protons) ppm. ³¹P NMR (CDCl₃): -1.83, -1.90 ppm. HRMS (ESI): Calcd. for $C_{46}H_{50}N_5O_{17P}$ [M+Na]⁺ 998.2837, Found 998.2802.

REFERENCES

- 1. Ichikawa, Eiko; Kato, Kuniki Sugar-modified nucleosides in past 10 years, a review. *Current Medicinal Chemistry* **2001**, 8, 385–423.
- 2. a) Grate, J.W.; Frye, G.C. in Sensors Update, (Eds): Baltes, H.; Göpel, W.; Hesse, J., Wiley-VCH. Weinheim, 1966, vol. 2, pp. 10-20. b) Szarek, W.A.; Pinto, B.M.; Iwakawa, M. Synthesis and biological activity of nucleoside analogues involving modifications in the carbohydrate ring. Can. J. Chem. 1985, 63, 2149-2161. c) Hronowski, L.J.; Szarek, W.A. Synthesis and biological evaluation of novel pyrimidine nucleoside analogues of 1,4-oxathiane, 1,4-dithiane, and 1,4-dioxane. J. Med. Chem. 1982, 25, 522–526. d) Prisbe, E.J. Synthesis and antiviral evaluation of 1,4-dioxane nucleoside analogueues related to nucleoside dialdehydes. J. Med. Chem. 1986, 29, 2445-2450. e) Mitsuaki, M.; Naoko, K.; Yamaizumi, Z.; Okamoto, Y.; Nagahara, K.; Takayanagi, H. Synthesis of a novel dioxane nucleoside having two bases, 2(R)-(5-fluorouracil-1-yl)-5(R)-hydroxymethyl-3(R)-(uracil-1-yl)-1,4-dioxane and its 2(S)-isomer, from uridine. Tetrahedron Lett. 1997, 38, 6841-6844. f) Szarek, W.A.; Vyas, D.M.; Achmatowicz, B., Synthesis of nucleoside analogues of 1,4-oxathiane, 1,4-dothiane, and 1,4-dioxane. J. Heterocycle. Chem. 1975, 12, 123–127. g) Van Aerschot, A.; Balzarini, J.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 1,4-dioxane, 1,4-oxathiane and morpholine nucleoside analogs. Nucleosides Nucleotides 1991, 10, 591-592. h) Van Aerschot, A.; Janssen, G.; Herdewijn, P., Nucleoside analogs with a 1,4-dioxane, 1,4-oxathiane or 1,4-oxazine ring structure as the carbohydrate fragment. Bulletin des Societes Chimiques Belges 1990, 99, 769-777.
- Sinha, N.D.; Biernat, J.; Mcmanus, J.; Köster, H., Polymer support oligonucleotide synthesis. XVIII: Use of -cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. *Nucleic Acids Res.* 1984, 12, 4539–4557.
- Baskaran, S.; Aurich, H.G.; Biesemeier, F.; Harms, K. Cycloadducts from highly functionalized nitrones and oximes as ligands in the enantioselective addition of diethylzinc to benzaldehyde. *J. Chem. Soc., Perkin Trans.* 1 1998, 22, 3717–3724.
- a) Nagashima, N.; Ohno, M. Selective monoalkylation of acyclic diols by means of dibutyltin oxide and fluoride salts. *Chem. Pharm. Bull.* 1991, 39, 1972–1982. b) Nagashima, N.; Ohno, M. An efficient O-monoalkylation of dimethyl L-tartrate via O-stannylene acetal with alkyl halides in the presence of cesium fluoride. *Chem. Lett.* 1987, 1, 141–144.

- 6. a) Marshall, J.A.; Andersen, N.H.; Hochstetler, A.R. Reduction of malonic enolates with lithium aluminum hydride. *J. Org. Chem.* **1967**, 32, 113–118. b) Shi, M.; Jiang, J.; Feng, Y., Chiral C₂-symmetric 2,3-disubstituted aziridine and 2,6-disubstituted piperidine as chiral ligands in the addition reaction of diethylzinc with arylaldehydes. *Tetrahedron: Asymmetry* **2000**, 11, 4923–4933. c) Marshall, J.A.; Beaudion, S. Stereoselective Synthesis of Higher Sugars by Homologation of Carbohydrate-Derived Enals with Nonracemic-(Silyloxy) Allylic Stannanes and Substrate-Directed Hydroxylation. *J. Org. Chem.* **1994**, 59, 6614–6619.
- a) Albizati, K.F.; Babu, S. etc. A synthesis of the HIV-protease inhibitor nelfinavir from D-tartaric acid. *Tetrahedron Lett.* 2001, 42, 6481–6485. b) Takano, S.; Kurotaki, A.; Sekiguchi, Y.; Satoh, S.; Hirama, M.; Ogasawara, K. Selective manipulation of hydroxy groups in (2S,3S)-threitol. *Synthesis* 1986, 10, 811–817.
- a) Vorbrüggen, H.; Krolikiewicz, K. Nucleoside syntheses. XXII. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. *Chem. Ber.* 1981, 114, 1234–1255. b) Vorbrüggen, H.; Höfle, G. Nucleoside syntheses. XXIII. On the mechanism of nucleoside synthesis. *Chem. Ber.* 1981, 114, 1256–1268.
- Colacino, E.; Sindona, G.; Gosselin, G.; Mathé, C. Synthesis and Biological Evaluation of Some 5-Nitro- and 5-Amino Derivatives of 2'-Deoxycytidine, 2',3'-Dideoxyuridine, and 2',3'-Dideoxycytidine. Nucleosides, Nucleotides Nucleic Acids, 2003, 22, 2013–2026.
- Fisher, E.F.; Caruthers, M.H., Color coded triarylmethyl protecting groups useful for deoxypolynucleotide synthesis. *Nucleic Acids Res.* 1983, 11, 1589–1599.
- a) Stütz, J.A.R.; Richert, C. Synthesis of a formamidine-protected 5'-amino-2',5'-dideoxyguanosine phosphoramidite and preparation of 5'-acylamidooligonucleotides. *Tetrahedron Lett.* 2004, 45, 509–513. b) Eisenfuhr, A.; Arora, P.S. A ribozyme with michaelase activity: synthesis of the substrate precursors. *Bioorg. Med. Chem.* 2003, 11, 235–249.
- Ferris, J.P.; Peyser, J.R. Rapid and efficient syntheses of phosphorylated dinucleotides. Nucleosides Nucleotides, 1994, 13, 1087–1111.
- 13. Gait, M.J. Oligonucleotide Synthesis, A Practical Approach, IRL PRESS: Oxford, Washington DC, 1984.
- Yu, Q.; Kaffarnik, S.; Carlsen, P. Synthesis of Optically Active 1,4-Dioxane Nucleotide Analogues, Synth. Commun., 2008, 38, 4250–4264.